Dr Thomas Andrew, F. Hoffmann-La Roche AG, Basel

Discovery of Bitopertin: A potent and selective GlyT1 inhibitor (GRI) for the treatment of Schizophrenia 

Start Date 28.02.2013 - 14:00
Event End 01.03.2013 - 15:00
Location Université de Genève

Discovery of Bitopertin: A potent and selective GlyT1 inhibitor (GRI) for the treatment of Schizophrenia